Focused On-demand Library for Outer dynein arm-docking complex subunit 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96NG3

UPID:

ODAD4_HUMAN

Alternative names:

Tetratricopeptide repeat protein 25

Alternative UPACC:

Q96NG3; Q6NX40; Q6PJ04; Q9H0K5

Background:

Outer dynein arm-docking complex subunit 4, also known as Tetratricopeptide repeat protein 25, plays a pivotal role in the assembly of the outer dynein arm-docking complex (ODA-DC). This complex is crucial for the binding of outer dynein arms (ODA) onto the doublet microtubule, facilitating the essential function of ciliary axoneme in motility.

Therapeutic significance:

The protein's malfunction is linked to Ciliary dyskinesia, primary, 35, a condition characterized by motile cilia abnormalities leading to severe respiratory infections and potentially situs inversus in Kartagener syndrome. Understanding the role of Outer dynein arm-docking complex subunit 4 could open doors to potential therapeutic strategies for these ciliopathies.